CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. CFDs are leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved.

PolyNovo share price jumps 10% following $2 million December month

PolyNovo’s stock was first put into a voluntary trading halt before revealing an impressive set of NovoSorb BTM sales figures from the December (CY19) month.

It’s been a positively busy period for Polynovo shareholders.

As we wrote just recently in December:

‘News that Polynovo’s (ASX: PNV) NovoSorb BTM had been granted a certificate of conformance – sent the share price of the now $1.28bn tech-focused healthcare company up as much as 27%.'

This was a significant development for the fast-growing company, as it ‘will give PolyNovo the green light to sell its NovoSorb BTM product throughout the UK, Ireland and the European Union,’ we previously wrote.

PolyNovo share price: more bullish news

Building on those bullish developments, today PolyNovo provided the market with an update regarding its December and H1 FY20 sales performance.

Here, and on an unaudited basis, PolyNovo revealed that revenue from the company's cornerstone NovoSorb BTM product – for the December month (CY19) had reached $2m – representing a 134% increase from the December prior.

This was a first for the company.

Looking at the broad top-line growth in the 2020 fiscal year, the company further reported that H1 FY20 revenue came in at $8.57m – a significant increase from H1 FY19's revenue of $3.75m.

PolyNovo now boasts a market capitalisation of $1.2bn.

Speaking of sales 'ramping' up in recent times, PolyNovo's Chief Executive Officer, Paul Brennan said:

'We are pleased with the sales trend. However, as a word of caution sales will continue to be lumpy as new sales staff are added and new territories opened up and because of natural disasters such as fires and volcanoes.’

Other comments – focusing on the company’s expansionist plans also likely caught investor attention today, with Mr Brennan further noting:

‘The expansion of the US sales team is adding to the sales momentum and we expect to see further acceleration of sales as a result of increased in-territory sales and the wider territory coverage coming from new staff hires. We are appointing more salespeople in the US to drive revenue and we are still actively recruiting.'

In response to this news of PolyNovo’s ‘two million dollar month,’ the company’s share price rose 10.74% – to $2.01 per share – by 16:04 AEDT.

Other news: more developments still to come

The company reported that a full set of audited financial results will be released on February 26.

Polynovo (ASX: PNV) also commented that it would soon release additional information on the current EU/UK prospects following the company's recently received certificate of conformance. PolyNovo’s Chairman – David Williams – expects sales to accelerate as a consequence of this approval.


The information on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG Bank S.A. accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer.

Act on share opportunities today

Go long or short on thousands of international stocks with CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take your position.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices
liveprices.javascriptrequired
liveprices.javascriptrequired
liveprices.javascriptrequired

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.